Targeting BIGH3 in selected solid tumors through a pH-Dependent antibody engineering strategy
4 affiliations
- 1StromaCare SAS, Department of Research and Development, Lyon, France; Corresponding author.
- 2StromaCare SAS, Department of Research and Development, Lyon, France
- 3Abzena, Department of Research and Development, Cambridge, United Kingdom
- 4GCLIPS Biotech, Department of Research and Development, Toulouse, France
Abstract
Targeting highly abundant stromal antigens in solid tumors is often limited by antigen sink effects, which reduce therapeutic exposure and compromise efficacy. Transforming growth factor beta-induced protein ig-h3 (TGFBI/BIGH3) is a secreted extracellular matrix (ECM) protein overexpressed in multiple malignancies and involved in tumor progression and immune modulation, yet its high circulating levels present a major challenge for antibody-based targeting. Here, we report that structural characterization suggested an increased oligomerization of BIGH3 in the tumor microenvironment (TME)-mimicking conditions without detectable loss of antibody binding and affinity (Equilibrium dissociation constant (KD) or half-maximal effective concentration (EC50)). We also demonstrate that pH-sensitive anti-BIGH3 antibodies can be engineered to preferentially bind under acidic conditions that mimics the TME while reducing binding under physiological pH. Through iterative humanization, oligomerization assessment, fragment crystallizable region (Fc) optimization, and structure-guided mutagenesis, we generated variants exhibiting robust tumor-relevant binding combined with reduced affinity at neutral pH. Biophysical analyses confirmed preserved stability and manufacturability profiles, while in vitro studies demonstrated pH-dependent target engagement and in vivo studies showed anti-tumor effect in colorectal cancer mouse model. These findings support the feasibility of a strategy aimed at mitigating antigen sink by exploiting tumor-associated pH gradients, although direct in vivo pharmacokinetic (PK), biodistribution and tumor accumulation studies remain to be performed. Collectively, this work provides a proof-of-concept (PoC) framework for the development of conditionally active antibodies targeting highly expressed extracellular antigens in solid tumors and highlights pH-dependent engineering as a potentially generalizable approach to improve therapeutic index.
Related
- Antibody Targeting Soluble NKG2D Ligand MIC Enhances Adoptive T-Cell Therapy in an NK Cell-Dependent Mechanism
- A Cell-based Screening Method Using an Intracellular Antibody for Discovering Small Molecules Targeting Hard-to-drug Proteins
- A neutralizing monoclonal antibody targeting species B adenoviruses largely mimics the DSG2 receptor engagement mechanism
- Structural basis for cross-alphaherpesvirus neutralization by an antibody targeting a conserved hotspot on glycoprotein B
- 548 A phase 1 first-in-human study of ZM008, a novel IgG1 monoclonal antibody targeting LLT1, as monotherapy and combined with toripalimab in patients with advanced solid tumors
BibTeX
@article{aguera2026targeting,
title = {{Targeting BIGH3 in selected solid tumors through a pH-Dependent antibody engineering strategy}},
author = {Karine Aguéra and Sahar Kassem and Sophie Bachy and Arron Hearn and Dawn Bembridge and Farnoush Masoudzadeh and Héliciane Palenzuela and Rosie Dawaliby and Georges Rawadi},
journal = {Biochemistry and Biophysics Reports},
year = {2026},
month = oct,
doi = {10.1016/j.bbrep.2026.102769},
url = {https://doi.org/10.1016/j.bbrep.2026.102769},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Targeting BIGH3 in selected solid tumors through a pH-Dependent antibody engineering strategy
AU - Karine Aguéra
AU - Sahar Kassem
AU - Sophie Bachy
AU - Arron Hearn
AU - Dawn Bembridge
AU - Farnoush Masoudzadeh
AU - Héliciane Palenzuela
AU - Rosie Dawaliby
AU - Georges Rawadi
PY - 2026
DA - 2026/10/16
JO - Biochemistry and Biophysics Reports
DO - 10.1016/j.bbrep.2026.102769
UR - https://doi.org/10.1016/j.bbrep.2026.102769
AB - Targeting highly abundant stromal antigens in solid tumors is often limited by antigen sink effects, which reduce therapeutic exposure and compromise efficacy. Transforming growth factor beta-induced protein ig-h3 (TGFBI/BIGH3) is a secreted extracellular matrix (ECM) protein overexpressed in multiple malignancies and involved in tumor progression and immune modulation, yet its high circulating levels present a major challenge for antibody-based targeting. Here, we report that structural characterization suggested an increased oligomerization of BIGH3 in the tumor microenvironment (TME)-mimicking conditions without detectable loss of antibody binding and affinity (Equilibrium dissociation constant (KD) or half-maximal effective concentration (EC50)). We also demonstrate that pH-sensitive anti-BIGH3 antibodies can be engineered to preferentially bind under acidic conditions that mimics the TME while reducing binding under physiological pH. Through iterative humanization, oligomerization assessment, fragment crystallizable region (Fc) optimization, and structure-guided mutagenesis, we generated variants exhibiting robust tumor-relevant binding combined with reduced affinity at neutral pH. Biophysical analyses confirmed preserved stability and manufacturability profiles, while in vitro studies demonstrated pH-dependent target engagement and in vivo studies showed anti-tumor effect in colorectal cancer mouse model. These findings support the feasibility of a strategy aimed at mitigating antigen sink by exploiting tumor-associated pH gradients, although direct in vivo pharmacokinetic (PK), biodistribution and tumor accumulation studies remain to be performed. Collectively, this work provides a proof-of-concept (PoC) framework for the development of conditionally active antibodies targeting highly expressed extracellular antigens in solid tumors and highlights pH-dependent engineering as a potentially generalizable approach to improve therapeutic index.
SN - 2405-5808
ER -